Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04896658 · ClinicalTrials.gov registry record · Phase 1
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04896658 is a Phase 1 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 10 participants.
The verdict
NCT04896658, a Phase 1 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma
Interventions
- DRUG Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-12-03 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04896658
The ClinicalTrials.gov registry entry for NCT04896658 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belantamab Mafodotin, Cyclophosphamide and Dexamethasone is the first listed.
NCT04896658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04896658 about?
NCT04896658 is a clinical study titled "Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma". Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma
What is the current status of trial NCT04896658?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2021-12-03. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT04896658?
The interventions under investigation include: Belantamab Mafodotin, Cyclophosphamide and Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT04896658?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.